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Background: Variation in physiological deficits underlying upper limb paresis after stroke 
could influence how people recover and to which physical therapy they best respond.
Objectives: To determine whether functional strength training (FST) improves upper 
limb recovery more than movement performance therapy (MPT). To identify: (a) neural 
correlates of response and (b) whether pre-intervention neural characteristics predict 
response.
Design: Explanatory investigations within a randomised, controlled, observer-blind, 
and multicentre trial. Randomisation was computer-generated and concealed by an 
independent facility until baseline measures were completed. Primary time point was 
outcome, after the 6-week intervention phase. Follow-up was at 6 months after stroke.
Participants: With some voluntary muscle contraction in the paretic upper limb, not 
full dexterity, when recruited up to 60 days after an anterior cerebral circulation territory 
stroke.
interventions: Conventional physical therapy (CPT) plus either MPT or FST for up to 
90 min-a-day, 5 days-a-week for 6 weeks. FST was “hands-off” progressive resistive 
exercise cemented into functional task training. MPT was “hands-on” sensory/facilitation 
techniques for smooth and accurate movement.
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Outcomes: The primary efficacy measure was the Action Research Arm Test (ARAT). 
Neural measures: fractional anisotropy (FA) corpus callosum midline; asymmetry of 
corticospinal tracts FA; and resting motor threshold (RMT) of motor-evoked potentials.
analysis: Covariance models tested ARAT change from baseline. At outcome: 
correlation coefficients assessed relationship between change in ARAT and neural mea-
sures; an interaction term assessed whether baseline neural characteristics predicted 
response.
results: 288 Participants had: mean age of 72.2 (SD 12.5) years and mean ARAT 25.5 
(18.2). For 240 participants with ARAT at baseline and outcome the mean change was 
9.70 (11.72) for FST + CPT and 7.90 (9.18) for MPT + CPT, which did not differ statisti-
cally (p = 0.298). Correlations between ARAT change scores and baseline neural values 
were between 0.199, p = 0.320 for MPT + CPT RMT (n = 27) and −0.147, p = 0.385 for 
asymmetry of corticospinal tracts FA (n = 37). Interaction effects between neural values 
and ARAT change between baseline and outcome were not statistically significant.
conclusions: There was no significant difference in upper limb improvement between 
FST and MPT. Baseline neural measures did not correlate with upper limb recovery or 
predict therapy response.
Trial registration: Current Controlled Trials: ISRCT 19090862, http://www.controlled- 
trials.com
Keywords: stroke, rehabilitation, physical therapy, transcranial magnetic stimulation, magnetic resonance 
imaging, upper limb; prediction
development of physical therapies for driving beneficial neuro­
plasticity (15, 19, 21). A particular benefit is expected to be 
provision of targets for physical therapy. For instance: focus­
sing measurement of response on non­primary cortical motor 
areas, including premotor and supplementary motor area 
(19, 22) especially when there is greater damage to the corticospi­
nal system (23, 24). Scientific advances are also expected from a 
greater understanding of how the characteristics of an individual 
influence their therapy­induced response (15, 20, 21). More spe­
cifically, by providing predictive markers of response to different 
physical therapies to enable stratification of therapy to stroke 
survivors based on their probability of response. Such an advance 
would enable clinical trials of specific physical therapies in those 
most likely to respond, thus reducing estimated sample sizes and 
avoid inclusion of those who are unlikely to benefit (15, 25). There 
are already experimental indications that the pre­intervention 
degree of injury to descending white matter pathways (26, 27) 
and primary motor cortex activity during movement (28) could 
be associated with therapy­induced recovery. Needed now are 
adequately powered trials which employ objective sensitive neu­
ral measures to improve understanding of how specific physical 
therapies enhance recovery (mechanisms for targeted therapies) 
and which people are most likely to respond (predictive markers 
of therapy­induced response) (14–16, 18, 19, 29). This approach 
has been used successfully to investigate language recovery (30) 
and is expected to add specific information to evidence­based 
algorithms to assist therapists to prescribe physical therapy for 
people with stroke (31).
inTrODUcTiOn
Upper limb recovery after stroke has been identified as a top 10 
research priority by people with stroke (1). This is not surprising 
because approximately 77% of people with stroke experience 
upper limb dysfunction (2), which impacts adversely on inde­
pendence with everyday tasks such as drinking from a cup and 
fastening buttons (3). Despite benefits from physical therapy after 
stroke (4) for those people with initial severe paresis only around 
40% will achieve some dextrous hand function at 6 months after 
the ictus (5, 6). Specifically; there is evidence for benefit from 
interventions based on repetitive task­specific training (7); the 
first 3 months after stroke could be the most crucial for rehabilita­
tion (8); and there is greatest potential for neural reorganisation 
(neuroplasticity) (9). However, there is an increasing understand­
ing that not everybody responds in the same way to specific 
physical therapies. For example, constraint­induced movement 
therapy is probably only suitable for people 3–9  months after 
stroke (10, 11) who are able to produce voluntary extension of 
at least 10° in the contralesional wrist and two fingers (12, 13). 
Essentially, there is variation in the physiological deficits result­
ing from stroke, which may influence how people recover and to 
which intervention they best respond (14). Therefore, progress 
requires greater understanding of the neurophysiology of 
therapy­induced response and which people are likely to benefit 
from which physical therapy (9, 14–21).
Greater understanding of the neurophysiological mecha­
nisms of therapy­induced response is expected to inform the 
3Hunter et al. FAST-INdiCATE: Efficacy, Correlates, Predictive Markers
Frontiers in Neurology | www.frontiersin.org January 2018 | Volume 8 | Article 733
The trial reported here investigated the predictors of response 
to and mechanisms of response to specific physical therapies in 
subgroups of people early after stroke. It also addressed the lack of 
investigation of the cost­effectiveness of physical therapy interven­
tions (21). The two well­characterised physical therapies providing 
the context for investigation are used in conventional physical 
therapy (CPT): functional strength training (FST) focussed on 
improving the ability to perform everyday tasks (32–41); and 
movement performance therapy (MPT) focussed on improving 
the quality of movement during performance of everyday tasks (32, 
39–43), referred to as extra CPT in early phase studies (32, 39–41). 
A recent systematic review concluded that such conceptually 
different physical therapies are probably no less or more effective 
than each other (4) although early phase trials indicate variation 
between people in their response to FST and MPT (32, 41, 44, 45).
The main aims for the trial reported here were as follows:
 1. to determine whether there is greater clinical efficacy for FST 
that for MPT when given in addition to CPT early after stroke 
(FST + CPT and MPT + CPT);
 2. to explore similarities and differences in neural correlates of clini­
cal improvement in response to FST + CPT and MPT + CPT;
 3. to explore the relationship between baseline measurements 
and improvement in upper limb motor function in response 
to FST + CPT and MPT + CPT.
In addition, we aimed:
 4. to provide estimates of cost­effectiveness of FST + CPT versus 
MPT + CPT in preparation for the development of any subse­
quent studies.
MaTerials anD MeThODs
The detailed trial protocol has been published (46) and is also 
available online (excluding the health economics component) 
in the report to funder (47). Consequently, the key methodo­
logical features have been previously reported and are therefore 
only summarised below. The trial was registered on Current 
Controlled Trial1 (ISRCTN 19090862) and adopted by the UK 
Clinical Research Network.
Design, randomisation, and ethics
A randomised, controlled, observer­blind, two­group, and mul­
ticentre trial. Baseline measures were made for each participant 
before random allocation to a group. Outcome measures were 
undertaken on the working day (±7 days) after the 6­week inter­
vention phase ended. Follow­up measures were undertaken six 
calendar months (±14 days) after the date of the index stroke. 
Clinical efficacy measures were made at each time point. Neural 
measures were made at baseline and outcome. For health eco­
nomics data, EQ 5­D data were collected at all three time points 
and resource use at follow­up.
An independently pre­generated randomisation sequence 
allocated participants into two groups stratified by: clinical centre 
(Stoke­on­Trent, Birmingham, Norwich); time (up to 30 days or 
1 http://www.controlled­trials.com.
31+ days) poststroke at time of providing informed consent: 
and substantial or moderate impairment in the contralesional 
(paretic) upper limb assessed by an inability to complete the 
Nine Hole Peg Test in 50 s (48) (substantial impairment = able 
to move one peg or less in 50 s, moderate impairment = able to 
move two or more pegs in 50  s.). Allocation concealment was 
maintained before computer­generated randomisation that was 
revealed by an independent telephone service for each participant 
after baseline clinical efficacy measures were completed.
At baseline (pre­randomisation) all assessors were blinded 
to group allocation. At outcome and follow­up, there were a few 
occurrences when a blinded assessor was unavailable. Every effort 
was made to ensure that all randomised participants undertook 
outcome and follow­up measures. When participants could not 
be included in an assessment the reason was documented.
Ethical approval was granted by the Norfolk Research Ethics 
Service (reference number 11/EE/0524).
Participants and screening
Adults aged 18+ years, after anterior circulation ischaemic or 
haemorrhagic stroke (confirmed by clinical neuroimaging) 
within the previous 2–60  days; scoring >11/33 on Motricity 
Index pinch subsection (49) with more paretic (contralesional) 
upper limb; unable to complete Nine­Hole Peg Test (48) in 50 s 
or less with paretic upper limb; no obvious spatial neglect [score 
of 0 or 1 on NIHSS Extinction and Inattention subsection (50)], 
no obvious dyspraxia or communication deficits (ability to 
imitate action with non­paretic limb following instruction); and 
able to lift a cup with paretic upper limb to take a drink before 
the index stroke.
Screening was undertaken in two stages. Stage 1 was under­
taken by research nurses employed through UK National Institute 
of Health Research funding. The research nurses screened for: 
age; time after stroke; that the stroke was in the territory of the 
anterior circulation; that medical stability/fitness to participate in 
therapy had been reached; and that the person had been able to use 
their more paretic upper limb before the index stroke. Informed 
consent was taken by either the research nurses or a clinically 
qualified member of the research team. Stage 2 screening for 
the remaining cognitive and motor criteria was undertaken by a 
clinically qualified member of the research team.
sample size
The sample size calculation was based on Action Research Arm 
Test (ARAT) (51) data from the early phase trial of FST + CPT 
and MPT +  CPT for the upper limb (32). The power calcula­
tion accounted for the three centres and clustering in the design 
(participants, within a therapist within a group) and allowed for a 
10% attrition rate. This provided an estimated sample size of 288 
(144 participants per group) with 80% power to detect a clinically 
important mean difference (6.2 points on the ARAT), applying a 
5% two­sided significance level.
interventions
The interventions have been described in detail elsewhere 
(47, 52–54). Consequently, only the essential elements pertinent 
to the present trial are here. The actual dose and content of therapy 
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received by participants are detailed in the results section of this 
report.
All participants continued to receive routine CPT throughout 
the trial provided by the usual clinical team. The content and 
dose (amount in minutes) of CPT was recorded on a standardised 
form (52) using the same procedure as in earlier trials (32, 39–41, 
55–57). A CPT­only group was not employed in this trial since 
additional therapy is known to be beneficial (21, 58), and the 
routine dose of CPT may be suboptimal (32, 41, 55, 57, 59–61).
In addition to routine CPT, participants received their 
experimental intervention, either FST (FST  +  CPT) or MPT 
(MPT + CPT) according to their randomised group allocation. 
The clinical team was not told the group allocation of participants.
Experimental interventions were provided for up to 90 min/
day, 5 days a week (Monday–Friday), for a period of up to 6 weeks 
(6­week intervention phase). Intervention sessions were provided 
where participants were located: in­patient or out­patient facility, 
or in their own home. Therapy content and dose were recorded by 
the research therapists for each day on which people participated 
in their allocated intervention.
Experimental FST and MPT was prescribed and delivered, 
through direct and non­direct contact, by research therapists in 
each centre who were trained in wither FST or MPT according 
to a standardised manual. Training was provided before the first 
participant was randomised: any research therapist subsequently 
joining the trial after this point was provided with bespoke train­
ing before their first participant was randomised. During the 
course of the trial two group­training events were held, which 
provided refresher training, and enhanced the within­trial regu­
lar research therapist networking that was an important element 
of maintaining adherence to protocol across centres. Treatment 
fidelity was observed at each site on an ad hoc basis by a senior 
member of the research team.
Conventional Physical Therapy
Conventional physical therapy for stroke is a complex interven­
tion (62) that combines different treatment approaches and 
techniques to provide personalised treatment based on compre­
hensive patient assessment. In the UK, CPT for the paretic upper 
limb includes the intervention categories: hands­on therapy to 
mobilise joints/soft tissues; hands­on therapy and cueing to facili­
tate muscle activity and movement; positioning and splinting to 
promote normal alignment of body structures; somatosensory 
stimulation; strengthening exercise; functional activities; and 
education (52). CPT therefore includes both MPT and FST.
The strength training elements of CPT include strengthening 
exercise and functional activity retraining based on findings that 
upper limb muscle strength is associated with ability to perform 
activities of daily living (33–35, 63). However, in CPT, unlike the 
experimental FST (see Functional Strength Training), progression of 
strengthening exercises and functional task training is not system­
atic. Instead, functional activity is encouraged as voluntary activa­
tion improves but attention to movement performance parameters 
remains a focus. Progression of activity is based on clinical assess­
ment of movement performance in relation to these parameters.
The hands­on and sensory stimulation components of CPT, 
that focus on restoring movement quality, i.e., efficient, smooth, 
timely, coordinated movement with normal alignment or sym­
metry of body structures before retraining functional movement, 
is called MPT (39). The MPT elements of CPT consist of the 
hands­on therapy focussed on joint/soft tissue mobilisation, 
facilitation of muscle activity, and movement and somatosensory 
stimulation.
Movement Performance Therapy
Movement performance therapy is “therapist dependent,” particu­
larly in the presence of limited voluntary muscle activation. The 
research therapists monitored and provided intrinsic feedback on 
movement performance through skilled observation, handling 
and facilitation techniques. Therapist­led hands­on guidance 
and feedback assisted practice of functional tasks, sometimes 
with increasing resistance or mass of an object and changes in 
speed of movement to increase the challenge of the activity, but 
this was not progressed systematically. Replicated single system 
studies of one module of MPT, known as mobilisation and tactile 
stimulation delivered daily for up to 60 min/day, 5 days/week for 
6 weeks to the paretic upper limb of people in the subacute (54) 
and chronic phases after stroke (45) produced improvements in 
upper limb muscle strength and activity capacity.
Functional Strength Training
Functional strength training for the upper limb after stroke 
combines strength training of weaker muscles with task­specific 
training through “repetitive, progressive, resistance exercise dur­
ing goal­directed functional activity” (53). Research therapists 
provided external feedback and verbal prompting whilst only using 
hands­on contact for safety (“therapist­independent”). The focus 
was on achieving key components of upper limb function (reach 
and grasp) through systematic progression of resisted strengthen­
ing of muscles that lacked appropriate force during goal­directed 
functional activity. For example, progressive strengthening of 
muscles around the shoulder and elbow enables more appropriate 
placement of the hand during reach; and improving appropriate 
muscle force production in the forearm, wrist, and hand improves 
grasp and ability to manipulate objects (53). Thus, strength gains 
in one component of a task are transferred to improvements in 
the whole task (64). Variations in types of muscle contraction 
(isometric, isotonic, and isokinetic) (65), number of repetitions, 
speed, or range of movement/distance moved, resistance (grav­
ity, weights, and resistance bands), or changes to mass and shape 
of everyday objects used in the tasks, progresses the activities 
systematically (53). Using principles of repetitive task­specific 
training to relearn skilled movement and tasks, components 
of complex functional tasks are practiced (part practice) until 
the whole task can be completed actively and practiced (whole 
practice) with sufficiently high number of repetitions for motor 
learning (66) and cortical reorganisation (9).
Processing of Therapy Data
Dose of physical therapy is thought to be especially important as 
it has been associated with enhanced outcome [e.g., Ref. (21, 58)]. 
However, there are systematic review findings that different forms 
of physical therapy may confound any association (67). Therefore, 
the therapy data, amount (dose) and content, were extracted and 
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collated for each randomised participant from the standardised 
forms completed by the clinical (CPT) and research (FST and 
MPT) therapists. The total hours provided for each participant 
of CPT and their allocated experimental intervention (FST or 
MPT), total number of sessions of CPT and experimental therapy 
provided for each participant, the mean duration (minutes) of 
each therapy session for each participant, and the percentage of 
sessions in which the categories of CPT and experimental inter­
vention were provided, were calculated for each participant using 
Microsoft® Excel®. In addition, the percentage of experimental 
sessions lasting 90 min or more was calculated. The reasons for 
a duration of less than 90 min were collated as a percentage of 
experimental sessions delivered.
Outcomes—clinical efficacy
The time points for measures were before randomisation (base­
line), the working day (±7  days) after the 6­week intervention 
phase ended (outcome) and six calendar months (±14  days) 
after the date of the index stroke (follow­up). Outcome was the 
primary endpoint.
Primary Outcome Measure
The primary outcome measure was the ARAT as a measure of the 
expected effect of both experimental interventions: recovery of 
upper limb activity capacity (51).
Secondary Outcome Measures
The Wolf Motor Function Test (WMFT) as both an extended 
measure of upper limb activity capacity and the quality of move­
ment during the 15 test tasks (68, 69). Other measures were hand 
grip and pinch grip forces, direct measures of muscle strength 
using a myometer held securely in a purpose­built device placed 
on a stable surface and using a standardised position for upper 
limb position (70, 71).
Outcomes—neural
This report focuses on the prespecified neural outcomes, listed 
below, which were chosen to be congruent with recommenda­
tions for choice of biomarkers of motor recovery after stroke (25). 
Subsequent reports will present exploratory analyses of other 
measures derived from the neuroimaging data.
Neuroimaging
Neuroimaging was acquired on hospital or university 3T 
magnetic resonance imaging (MRI) scanners at each research 
site. These included a Siemens Skyra (Stoke­on­Trent), Philips 
3T Achieva (University of Birmingham), and GE Discovery 
MR750w (Norwich). Effort was made to match neuroimaging 
protocols across sites as far as possible, thought slight variation 
in scan sequences was unavoidable due to scanner differences. 
Scans included the following:
•	 A T1­weighted 1  mm ×  1  mm ×  1  mm, whole­brain image 
was obtained using structural MRI [Norwich (GE): BRAVO: 
TI/TE/TR  =  900/6/14.1  ms, FOV  =  25.6  cm, acquisition 
matrix  =  256  ×  256; Birmingham (Philips): 3DTFE: TI/
TE/TR  =  900/4.7/11.2  ms, FOV  =  25.6  cm, acquisition 
matrix  =  256  ×  256; Stoke­on­Trent (Siemens): Skyra: TI/
TE/TR =  900/3.51/2,040  ms, FOV =  256 ×  192, acquisition 
matrix = 256 × 256].
•	 Diffusion tensor imaging (DTI) scans were acquired at 
2 mm × 2 mm × 2 mm (64 isotropically distributed diffusion 
directions; b = 1,500; 62 slices; plus two sets of b = 0 images, 
one with phase encoding anterior to posterior, and the other 
with phase encoding posterior to anterior).
•	 Dual­echoT2­weighted and proton density whole brain MRI 
scans (GE: TE = 13 ms; TE2 = 101 ms; and TR = 4,670 ms) 
were acquired at 1 mm × 1 mm × 3 mm to enable accurate 
delineation of stroke volumes.
Task­based and resting state functional MRI data were also 
acquired when possible but are not reported here due to small 
subject numbers.
Each neuroimaging scan was sent promptly to the Oxford­
based team members to undertake quality control checks. 
Quality control assessments included manual checks (e.g., subject 
motion) and automated checks (e.g., signal to noise, motion 
correction parameters, and range checks). Those scans meeting 
the required quality standard were processed using tools from 
FMRIB’s Software Library (FSL2). The lesion was delineated 
manually on each patient’s T1­weighted 1 mm × 1 mm × 1 mm 
brain image using FSL view, an image viewing tool available 
within FSL.
Measures extracted were as follows:
•	 The anatomical overlap of the stroke lesion with the Montreal 
Neurological Institute corticospinal tract (MNI CST)—yes/
no: this variable identifies whether the lesion overlaps with 
a mask approximating the corticospinal tract. The CST mask 
was defined using tractography in a group of control brains in 
standard space to track between motor cortex and medullary 
pyramids. Overlap between the lesion volume and the CST 
was determined by overlaying the lesion mask, described 
earlier, with the CST mask.
•	 The volume of the stroke lesion (lesion volume, mm3): this 
variable was determined by calculating the volume of the 
manually defined stroke mask described earlier.
•	 Corticocortical anatomical connectivity as per fractional anio­
strophy from corpus callosum midline [fractional anisotropy 
(FA) MNI corpus callosum misline—range =  0–1]: DTI data 
were first corrected for head motion and eddy current using 
tools from FSL. A diffusion tensor model was then fitted to the 
preprocessed data to calculate voxel­wise values of FA. Mean FA 
from within a standard space region of interest, incorporating the 
whole corpus callosum on a midline brain slice, was calculated.
•	 Corticospinal anatomical integrity as per asymmetry of 
corticospinal tract FA (ipsilesional:contralesional MNI CST—
range = −1 to 1): regions of interest on a single slice at the 
level of the internal capsule were created to provide masks 
estimating the location of the CST. Mean FA from within these 
masks was calculated. A ratio of ipsilesional:contralesional 
values was calculated.
2 http://www.fmrib.ox.ac.uk/fsl.
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Transcranial Magnetic Stimulation (TMS)
Single pulse TMS was applied over the hand/arm area of the 
ipsilesional primary motor cortex (M1) to elicit a motor­evoked 
potential (MEP). The coil was oriented at approximately 45° to 
the sagittal plane, to induce posterior to anterior current flow 
across the motor strip in the primary motor cortex. Stimuli were 
delivered with a Magstim 2002 stimulator (The Magstim Company 
Ltd., UK) via a standard 70 mm figure­of­eight coil with intensi­
ties between 100 and 130% of active motor threshold. MEPs were 
detected in the electromyogram via skin surface electrodes placed 
over the more paretic extensor carpi radialis (pECR) and paretic 
biceps brachii (pBB) muscles. All EMG records were amplified 
(500–2 k), band pass filtered (20–1,000 Hz), and digitally sampled 
at 5  kHz (Digitimer Neurolog System) to be stored for offline 
analysis (Signal, CED). The resting motor threshold (RMT) was 
determined as the intensity at which at least 5 out of 10 stimuli 
evoked MEPs with a peak­to­peak amplitude of greater than 50 µV 
(72). Active motor threshold was determined during a slight con­
traction of the target muscles (BB and ECR) at approximately 20% 
of the maximal muscle strength (72). Measures extracted were 
focussed around threshold MEP measures as these are probably 
the most reliable (73):
•	 corticospinal functional connectivity as per presence or 
absence of a resting MEP for pBB (pMEPBB—yes/no);
•	 corticospinal functional connectivity as per presence or 
absence of a resting MEP for pECR [pMEPECR (yes/no)];
•	 RMT in pBB when MEP was present [RMTpBB (%)];
•	 RMT in pECR when MEP was present [RMTpEXR (% maxi­
mum stimulator output)].
A number of key measurements including TMS threshold, 
stimulation intensity, presence, or absence of an MEP were 
recorded on the trial TMS case report (CRF) form for each indi­
vidual and each session. These data were collated by the Clinical 
Trial Unit (CTU) to provide details on the number of participants 
who displayed an MEP in target muscles (ECR and BB) in both 
limbs at resting and active motor threshold.
Outcomes—health economics
Intervention Costs
We estimated the total NHS and Personal Social Services (PSS) 
cost, without separately estimating the cost of the therapy 
intervention visits. It was assumed that no additional training 
or equipment costs would be required to roll the MPT out into 
practice. If FST was to be rolled into practice some centres may 
not have the equipment used in this trial, e.g.: resistive exercise 
bands, therapy putty, foam tubing (to help hold pens/cutlery), and 
graded pinch pins. A log of all equipment purchases was kept. A 
log was kept for all training delivered, including workshop times 
for the trainer(s) (including preparation) and trainee(s), and 
distances travelled, accommodation, and room hire costs. The 
trainers were cost as Band 8a staff [£62 per hour of employment 
(74)], and those delivering therapy were cost as Band 6 staff [£44 
per employment hour (74)]. The total costs associated with both 
equipment and training were estimated and equally apportioned 
across all participants.
Other NHS and PSS Costs
At follow­up, participants were asked to provide details of the use 
of all health­care services (including social care) since the index 
stroke, i.e., last 6  months. Unit costs (2014/2015 financial year 
levels) were assigned to all reported items of resource (74–77). 
This enabled the total NHS and PSS costs to be estimated. No 
discounting was undertaken as the follow­up period was less than 
1 year.
For each health­care service, a Yes, No, or participant cannot 
remember option was available. Where a No was reported the 
costs for that item of resource were assumed to be 0 and if the 
participant reported that they could not remember, the data were 
assumed to be missing. If they answered Yes, they were asked to 
report details including the level of resource use for that item in 
the previous 6 months.
Participants were asked if they had consulted or been visited by 
a health­care professional. We assumed that participants included 
therapy intervention visits within reported data. Unit costs 
[e.g., Ref. (74, 76)] were assigned to all visits.
Participants were asked to report if they had taken any 
medication (prescribed by the doctor). Those who responded 
yes, were asked to report the name of the medication, along with 
the associated dosage and whether they were taking the drug 
on an ongoing basis. Unit costs were subsequently attached to 
each reported medication based on the net ingredient cost per 
item for the individual preparation (75). Where the medication 
dosage was unclear, the weighted average net ingredient cost per 
item for that medication was used, where the medication box 
was completed but that could not be matched to an individual 
preparation, the mean net ingredient cost per item for all items 
was used. It was assumed that prescriptions reported as ongoing 
at the follow­up point had been taken for the whole of the prior 
6 months, whereas those that were not reported as ongoing had 
only been taken once during the previous 6 months.
Participants were asked if they had been admitted to hospital. 
Those that responded with “yes” were asked to provide the admis­
sion and discharge date for each occasion. A unit cost per bed day 
(77) was assigned to each day of an admission.
Participants were asked if they had attended accident and 
emergency department (A&E). A unit cost (77) was assigned to 
each visit.
Participants were asked if they had stayed in another place 
of residence other than their own home (not including hospital 
admissions). Unit costs (74) were then assigned.
Finally participants were asked if they had received any further 
help/care (not reported previously). In the base­case analysis, 
unit costs (74) were only assigned to care that was reported to 
be provided by a professional carer but was not paid for by the 
participant.
Quality of Life
In line with the National Institute for Health and Clinical 
Excellence (NICE) methods guide (78), quality of life was meas­
ured using the EQ­5D­3L (79). Responses were converted into 
utility scores (80) using the York A1 tariff (81). Quality­Adjusted 
Life Year (QALY) scores were subsequently calculated at follow­up 
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using the total area under the curve approach (82) for all those 
who completed the EQ­5D­3L at baseline and follow­up.
adverse reactions and events
The potential adverse reactions to participation in the exercise­
based therapies evaluated in this trial were considered to be pain 
and fatigue. Pain was held to be an adverse reaction if: (a) a partici­
pant expressed onset of pain in the paretic upper limb (verbally or 
behaviourally); (b) this was sustained over four consecutive therapy 
occasions; and (c) the clinical team had no explanation of pain onset 
other than involvement in the trial reported here. Fatigue was held 
to be an adverse reaction if: (a) a participant had a decrease of two 
levels of the upper limb Motricity Index on two consecutive therapy 
occasions and (b) the clinical team could not attribute fatigue to 
anything other than involvement in the trial reported here. If either 
adverse reaction occurred the trial therapy was adjusted or stopped, 
whichever was most appropriate for an individual.
Adverse events were recorded in accordance with a standard 
operating procedure (SOP 25: latest version at http://www.nnuh.
nhs.uk/publication/sop­205­adverse­events/).
statistical analysis
Before the database lock and unblinding of group allocations, the 
statistical analysis plan (SAP) was agreed, signed, and dated. In 
the agreed SAP, the analysis plan adjusted for study site which was 
a change from original intention of also accounting for clustering 
of patients by therapist. This change was made because therapist 
changes during the course of the trial meant that participants did 
not receive treatment by the same therapist for across all of their 
experimental intervention sessions. The SAP did not include the 
health economics analysis or statistical analysis of therapy data, 
though some detail of the associated planned analysis was given 
in the published protocol (46).
Clinical Efficacy (Aim 1)
Change from baseline to outcome and follow­up in the clinical 
efficacy variables was analysed with analysis of covariance models. 
These were adjusted for the baseline values and randomisation 
strata (time after stroke, ability to use contralesional upper limb 
and clinical centre). A log or other appropriate transformation was 
applied where the outcome/follow­up distribution deviated from 
a normal distribution. Adjusted least squares mean difference and 
associated 95% confidence intervals (95% CIs) were calculated. 
The association (Pearson correlation coefficient) between the 
total dose of CPT plus either FST or MPT was scrutinised to 
check for influence on response to therapy dose received.
Neural Correlates of Clinical Improvement (Aim 2)
Associations between the changes from baseline to outcome of the 
neural variables and the clinical efficacy variables were assessed. 
The correlation coefficient was calculated for the two intervention 
groups separately and for combination of the groups.
Predictive Neural Markers of Clinical Improvement 
(Aim 3)
For each baseline covariate investigated as a potential predic­
tive marker of clinical improvement, the treatment effect was 
calculated within each level of the subgroup (adjusted as in 
the clinical efficacy analysis). An interaction term between 
randomised treatment and the baseline covariate was included 
in the model.
Estimates of Cost-Effectiveness (Aim 4)
In the base­case analysis a complete case approach (83) was 
undertaken, whereby participants were only included if the 
overall estimated cost to the NHS and PSS and the QALY score 
could be calculated.
For those participants with complete data, bivariate regression 
(84) was used to estimate the mean incremental cost between the 
two groups (mean difference in overall cost to the NHS and PSS) 
and the mean incremental effect (mean per participant difference 
in QALYs). Cost and effect regression analyses were run simulta­
neously, with age and sex included as covariates, plus the baseline 
EQ­5D score for the QALY regression.
The mean per participant incremental cost and incremental 
effect were subsequently used to estimate the incremental 
cost­effectiveness ratio (ICER) (80). In the UK, NICE refers to 
a cost­effectiveness threshold (λ) value of £20,000–30,000 per 
QALY (78), and we considered that an estimated ICER below 
£20,000 would indicate that the intervention constituted value 
for money. However, due to the potential for a negative ICER to 
be estimated (which could result from either a negative cost or 
negative effect), as there is potential for this to be misinterpreted 
(85), the net benefit was also calculated at λ = £20,000 per QALY. 
A positive value indicates that the intervention was estimated to 
be cost­effective at that threshold (85).
To estimate the level of uncertainty associated with the 
decision regarding cost­effectiveness, bootstrap resampling 
(86) (with 5,000 replications) was used to estimate the cost­
effectiveness acceptability curve (CEAC) (87). The CEAC depicts 
the probability of the intervention being cost­effective at various 
“willingness to pay” thresholds compared to standard care. Here, 
the probability was estimated at a λ (threshold) value of £20,000 
per QALY.
Sensitivity analyses (80) were undertaken to assess the robust­
ness of conclusions to changes in key assumptions. Within the 
first sensitivity analysis (SA1), overall NHS and PSS costs and 
QALYs were rerun following multiple imputation (88) to account 
for missing cost and outcome data. We performed multiple 
imputation in a single model using the mi impute command in 
Stata 14. In addition to the costs and EQ­5D scores, the MI model 
included age, sex, and treatment allocation. Imputation took place 
in twenty cycles, the estimates from which were then pooled and 
calculated using Rubin’s rules (89). In a further sensitivity analysis 
(SA2), the base­case analysis was replicated but we excluded 
the intervention costs relating to training and equipment, on 
the assumption that these costs would not need to be incurred 
again if the intervention continued. The third sensitivity analysis 
(SA3) additionally included professional carer costs if they were 
reported to be paid for by the participant. A fourth sensitivity 
analysis (SA4) included these professional carer costs as well 
as any other care that the participant reported receiving, where 
the reported hours of care were assigned the mean hourly pay 
for all UK employees (90). A fifth sensitivity analysis (SA5) was 
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undertaken to assess whether results were particularly sensitive to 
outliers using data for participants whose estimated overall cost 
to the NHS and PSS was above the 95th percentile and below the 
5th percentile was excluded from the analysis.
Trial Management
Trial data were collected in accordance with trial operating proce­
dures, developed before the first participant was randomised, to 
the standard required in the SOPs agreed for use by the University 
of East Anglia (trial sponsor). The completed case report forms 
(CRF) were secured in a locked filing cabinet in research offices 
at each centre. When the trial follow­up phase was complete, all 
CRFs were transferred securely to the University of East Anglia 
where the final data query resolution was undertaken before 
database hardlock. All CRFs are stored securely at the University 
of East Anglia where they will be archived.
The data management team at the Glasgow CTU set up and 
managed the trial database in accordance with a data manage­
ment plan. This included procedures for maintaining blinding, 
and limited access of members of the trial team to data through­
out the trial. For example, data were sent to the Glasgow CTU 
in a secure standardised manner for database entry and quality 
control checks. An SAP for the clinical efficacy and explanatory 
data was agreed between the Glasgow CTU and research team 
before database lock and unblinding of group allocation.
The therapy data (content and dose of CPT, FST, and MPT) 
were not considered essential to answer the trial aims by the 
Glasgow CTU. Consequently, the trial sponsor (UEA) agreed 
an independent quality control review of: (a) the therapy data 
in the raw database supplied by the Glasgow CTU and (b) the 
processing undertaken by the research team using Microsoft® 
Excel® spreadsheets to provide values for statistical analysis. The 
values used in the statistical analysis have therefore been quality 
assured by an auditor independent of the research team.
A Trial Steering Committee (TSC) with independent chair and 
members was convened to provide overall supervision and ensure 
good conduct of the trial. The TSC met on nine occasions.
A Data Monitoring and Ethics Committee (DMEC), with inde­
pendent chair and members appointed by the funder, reported 
directly to the chair of the TSC. The DMEC met six times.
resUlTs
Flow of Participants through the Trial
The CONSORT flowchart for this trial (Figure 1) shows that 5,064 
people with stroke were screened by the research nurses (stage 1), 
of whom 1,263 (24.9%) were potentially eligible for this trial. 
However, 536 (42.4%) of those declined to talk to the research 
team and the research team were unavailable to talk with one 
potential participant. A further 207 people declined informed 
consent and 38 were unable to provide informed consent. The 
remaining 481 provided informed consent and undertook stage 
2 screening with a clinically qualified research team member. Of 
the 481 potential participants, 138 did not meet the cognitive 
and motor criteria and a further 55 either withdrew informed 
consent or were not randomised (reasons detailed in Figure 1). 
Consequently, 288 (5.7%) of the 5,064 people screened were 
randomised into this trial; 145 were allocated to FST + CPT and 
143 to MPT + CPT. The attrition rate at outcome was 12.5% and 
at follow­up was 27.8%.
MR scans were undertaken by those participants who had 
no contraindications, had provided separate informed consent 
for this part of the assessment, and who could travel to the 
neuroimaging facility. MR scans were undertaken for 94 (32.6%) 
of participants at baseline and 62 (23.0%) at outcome (Table 1). 
Reasons for non­completion of MRI recorded in the hard­locked 
raw database, are shown in Table 1.
Transcranial magnetic stimulation was undertaken by those 
participants who had no contraindications. The TMS measures 
were made with 111 (38.5%) participants at baseline and 83 
(30.2%) at outcome (Table 1). Reasons for no TMS as recorded 
in the hard­locked database are shown in Table 1.
Participant characteristics at Baseline
Table 2 provides details of the demographic and clinical (efficacy) 
characteristics of participants randomised into this trial. In sum­
mary: mean (SD) age was 72.2 (12.5) years, with 64.6% male. The 
anterior circulation stroke lesions were classified as hemorrhagic 
for 8.7% of participants and ischaemic for 91.3%. The left side of 
the body was more affected (paretic side) for 58.0% of partici­
pants. Of the 288 participants, 59% provided informed consent 
within 30 days of stroke.
The neural characteristics of those participants undertaking 
MR scans and/or TMS are shown in Table  3. The number of 
participants ranged from 80 (for corticocortical connectivity and 
corticospinal connectivity) to 110 (for MEPs in biceps brachii and 
extensor carpi radialis). Values were as follows: corticocortical 
connectivity was mean 0.4 (SD 0.08); corticospinal connectivity 
was mean 0.0 (SD 0.05); and lesion volume (mm3) was median 
4,293 (IQR 845.50, 17,160). MEPs were present in biceps brachii 
for 73% of the 110 measured participants; and in extensor carpi 
radialis for 76% of the 110 measured participants. There were no 
discernible differences between the FST + CPT and MPT + CPT 
groups at baseline.
Dose and content of Therapy received by 
all randomised Participants
In accordance with the intention­to­treat principle, the therapy 
data presented in this report are for all randomised participants 
not just those still remaining in the trial at outcome and/or 
follow­up. The FST + CPT group received a mean (SD) of 7.4 
(6.7) hours of CPT during the 6­week intervention phase in 12.9 
(8.9) sessions per individual. This compares to a mean (SD) of 
6.7 (5.8) hours of CPT for the MPT + CPT group in 12.1 (8.7) 
sessions. Thus, the amount of CPT delivered to both groups was 
essentially no different.
The mean (SD) number of hours of experimental therapy was 
14.8 (SD 9.9) for the FST + CPT group, and 19.2 (11.1) for the 
MPT + CPT group. In total the MPT + CPT group received 4.4 h 
more of experimental therapy than the FST +  CPT group but 
the variances around means were large (Table 4). This amount 
of therapy was delivered in a mean (SD) of 18.0 (8.6) sessions for 
FigUre 1 | All centres: CONSORT 2010 flow diagram.
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the FST + CPT group and 19.1 (7.9) for the MPT + CPT group 
(Table 4).
The mean (SD) duration (minutes) for each CPT therapy ses­
sion was 30.6 (12.9) for the FST + CPT group and 30.5 (13.2) for the 
MPT + CPT group (Table 4). The experimental therapy sessions 
lasted longer with a mean (SD) of 46.2 (16.9) and 57.6 (17.9) min 
for the FST + CPT and MPT + CPT groups, respectively. This 
difference was not statistically significant (independent samples 
t­test; t = 0.271, p = 0.633).
The median (IQR) percentage of sessions lasting at least 
90 min was 0.0 (0.0, 9.2) for the FST + CPT group and 8.3 (0.0, 
33.3) for the MPT + CPT group. Table 4 provides details of the 
reasons for sessions lasting less than 90 min recorded on the case 
report forms as: fatigued; unwell; declined; or other.
TaBle 2 | Participant characteristics, demographics, and clinical (efficacy), at 
baseline.
statistic FsT + cPT 
(n = 145)
MPT + cPT 
(n = 143)
all (n = 288)
Age (years) Mean (SD) 71.9 (12.7) 72.4 (12.3) 72.2 (12.5)
Sex Male (%) 96 (66.2) 90 (62.9) 186 (64.6)
Female (%) 49 (33.8) 53 (37.1) 102 (35.4)
Type of stroke Ischaemic (%) 131 (90.3) 132 (92.3) 263 (91.3)
Haemorrhagic (%) 14 (9.7) 11 (7.7) 25 (8.7)
Side of brain 
lesion
Left (%) 63 (43.5) 58 (40.6) 121 (42.0)
Right (%) 82 (56.5) 85 (59.4) 167 (58.0)
NHPT at  
consent
1 peg or less (%) 91 (62.8) 90 (63.0) 181 (62.9)
2–8 pegs (%) 54 (37.2) 53 (37.1) 107 (37.2)
Days after stroke 
at consent
≤30 days (%) 86 (59.3) 84 (58.7) 170 (59.0)
31 days+ (%) 59 (40.7) 59 (41.3) 118 (41.0)
ARAT total—
contralesional
Mean (SD) 24.7 (18.9)a 26.2 (17.4)a 25.5 (18.2)a
WMFT—
performance
Mean (SD) 36.4 (20.25)b 37.6 (17.1)b 37.0 (18.8)b
Grip force (kg) Mean (SD) 7.6 (8.7)c 6.9 (8.1)c 7.2 (8.4)c
Pinch force (kg) Mean (SD) 2.2 (2.2)d 1.9 (2.3)d 2.1 (2.2)d
NHPT, Nine-Hole Peg Test; ARAT, Action Research Arm Test; WMFT, Wolf Motor 
Function Test; FST, functional strength training; CPT, conventional physical therapy; 
MPT, movement performance therapy.
aNumber of data sets available for analysis were as follows: FST + CPT = 144; 
MPT + CPT = 139; and all = 283.
bNumber of data sets available for analysis were as follows: FST + CPT = 136, 
MPT + CPT = 129; and all = 265.
cNumber of data sets available for analysis were as follows: FST + CPT = 141, 
MPT + CPT = 139; and all = 280.
dNumber of data sets available for analysis were as follows: FST + CPT = 131, 
MPT + CPT = 133; and all = 264.
TaBle 1 | Magnetic resonance imaging (MRI) (neuroimaging) and transcranial 
magnetic stimulation (TMS) data acquisition at baseline and outcome.
Baseline 
(n = 288a)
Outcome 
(n = 245a,b)
number % number %
Mri data
Attended for neuroimaging 94 32.6 62 23.0
Unable to attend, unwell or unable to contact 35 12.2 46 17.1
Did not consent for MRI 56 19.4 71 26.4
Site approval, governance, or protocol not 
yet in place
32 11.1 23 8.6
Deemed unsuitable for MR, e.g., unable lie 
flat
8 2.8 3 1.1
Contraindications to MR 44 15.3 37 13.8
Scanner not available 17 5.9 16 6.0
No baseline scan – – 3 1.1
Out of area, in nursing home or SAE 1 0.3 8 3.0
Out of protocol time limit 1 0.3 0 0.0
TMs data
Attended for TMS 111 38.5 83 30.2
Did not consent for TMS 37 12.8 43 15.6
Unable to attend 25 8.7 44 16.0
Site approval, governance, or protocol not 
yet in place
12 4.2 13 4.7
Deemed unsuitable for TMS 6 2.1 0 0.0
Contraindications to TMS 69 24.0 64 23.3
Concomitant disease 1 0.3 1 0.4
TMS not available 24 8.3 16 5.8
Out of area, in nursing home or SAE 3 1.0 8 2.9
Data missing 0 0.0 3 1.1
aData obtained from Clinical Trial Unit (CTU) locked raw database.
bCTU outcome data account for: 269 participants in terms of attendance and non-
attendance for MRI scanning; and 275 participants in terms of attendance and non-
attendance for TMS (n = 245 refers to the number of participants with a total score for 
the Action Research Arm Test at outcome).
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The check for influence on response to the actual therapy dose 
received found no statistically significant correlation between the 
total hours and change in ARAT score from baseline to outcome. 
The results of the correlation analysis are: FST +  CPT group 
(n =  101) r =  0.154, p =  0.123; MPT + CPT group (n =  103) 
r = −0.055, p = 0.581; and for all participants (n = 204) r = 0.071, 
p = 0.311 (Figure 2).
The content of the CPT delivered to participants by the clini­
cal therapists is detailed in Table 5. In summary, the percentage 
of sessions in which specific modalities of CPT were provided 
for both groups was, essentially no different. All participants 
received the experimental intervention to which they had been 
allocated. For the FST + CPT group a median of between 73.2 and 
100.0% of sessions, across four “therapist­independent” treat­
ment categories, focussed on improving the ability to produce 
voluntary contraction in specific muscles required for upper 
limb function combined with training the ability to perform 
everyday functional tasks. This compares with the MPT + CPT 
group, where a median of: 100% of the therapist­dependent 
sessions included isolated joint movement and mobilisation; 
75% included facilitation of muscle activity and movement; 51% 
included positioning; 46% included specific sensory input; and 
31% included soft tissue mobilisation (Table 5). Although 93% of 
sessions included upper limb functional tasks and 69% included 
exercise to increase strength, there are differences between these 
FST and MPT categories not least that MPT is provided through 
“hands­on techniques.” These differences are delineated in the 
intervention protocols (47, 52–54).
clinical efficacy
There were 126 participants in the FST +  CPT group and 114 
in the MPT + CPT group who had a total score for the primary 
outcome of ARAT at both baseline and outcome, i.e., all sections 
completed on the case report form (Table 6). By follow­up, the 
number of participants with full ARAT scores also at baseline 
had dropped to 104 for the FST + CPT group and 100 for the 
MPT + CPT group (Table 6). Mean (SD) ARAT change scores 
(baseline to outcome) were clinically important for both groups: 
FST + CPT =  9.70 (11.72) and MPT + CPT =  7.90 (9.18). At 
follow­up, further mean (SD) ARAT change scores from baseline 
were evident for both groups: FST + CPT = 11.10 (14.68) and 
MPT  +  CPT  =  10.3 (10.74). However, at neither time point 
was the small between­group difference statistically significant: 
p = 0.298 at outcome and p = 0.743 at follow­up (Table 6).
Improvements for the secondary clinical efficacy outcome 
measures (Table 7) showed a similar pattern to the ARAT scores 
(primary outcome) in that improvements happened over the 
timecourse of the trial for both groups. However, the small 
differences between the two intervention groups did not reach 
statistical significance.
TaBle 3 | Neural values, by treatment group and overall, at baseline.
FsT + cPT MPT + cPT all
corticocortical connectivitya
Number 42 38 80
mean (SD) 0.4 (0.09) 0.4 (0.08) 0.4 (0.08)
Median (IQR) 0.4 (0.34–0.47) 0.4 (0.34–0.49) 0.4 (0.34–0.47)
corticospinal connectivity
Number 42 38 80
Mean (SD) 0.0 (0.04) 0.0 (0.05) 0.0 (0.05)
Median (IQR) 0.0 (0.01–0.06) 0.0 (−0.02 to 0.06) 0.0 (0.001–0.06)
lesion volume (mm3)
Number 44 40 84
Mean (SD) 23,847.89 
(47,664.63)
25,476.38 
(59,957.23)
24,623.36 
(53,542.90)
Median (IQR) 6,537.50 
(1,067.50–
19,551.50)
2,486.00 
(474.00–14,046.50)
4,293.00 
(845.50–17,160.50)
MeP present pBB
Number 53 57 110
Yes (%) 37 (69.81%) 43 (75.44%) 80 (72.73%)
RMT number 37 57 110
RMT mean (SD) 61.1 (11.49) 63.0 (14.39) 62.1 (13.08)
RMT median (IQR) 60.0 (54–66) 66.0 (53–74) 60 (54–70)
No (%) 16 (30.19%) 14 (24.56%) 30 (27.27%)
MeP present pecr
Number 53 57 110
Yes (%) 39 (73.58%) 45 (78.95%) 84 (76.36%)
RMT number 39 44 83
RMT mean (SD) 52.4 (12.30) 54.5 (15.27) 53.5 (13.91)
RMT median (IQR) 50 (46–58) 52.5 (44–61) 51.0 (45–60)
No (%) 14 (26.42%) 12 (21.05%) 26 (23.64%)
MEP, motor-evoked potential; pBB, paretic biceps brachii; RMT, resting motor 
threshold (% stimulator output); pECR, paretic extensor carpi radialis; FST, functional 
strength training; CPT, conventional physical therapy; MPT, movement performance 
therapy; FA, fractional anisotropy.
aFA MNI corpus callosum midline, range 0–1.
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neural correlates of clinical improvement
Change in neural variables derived from neuroimaging between 
baseline and outcome for those participants with data at both 
visits, and ARAT data at both visits are shown in Table 8. There 
were no statistically significant differences between the two groups 
for change in any of these variables. Change between baseline and 
outcome for RMT for pBB and pECR muscles for those participants 
with data at both visits and ARAT data at both visits is shown in 
Table 8. There were no statistically significant differences between 
the two groups for change in either of these variables.
The correlations between baseline to outcome change scores 
for neural variables and ARAT scores ranged from r = −0.001 
(p  =  0.996) for RMT pECR (all participants) to r  =  −0.306 
(p = 0.232) for the MPT + CPT group for corticospinal anatomi­
cal connectivity (Table  9). No significant correlations between 
ARAT improvement and neural measures were identified in 
either group or overall.
Predictive neural Markers of clinical 
improvement
For those people with both ARAT and neural data at baseline 
and outcome, there were no statistically significant interaction 
effects (Table 10).
adverse reactions and adverse events
Four participants in the FST + CPT group experienced an adverse 
reaction (for pain n = 1, and for fatigue n = 3). Two people in 
the MPT + CPT group experienced an adverse reaction (for pain 
n = 1, and for fatigue n = 1).
Adverse events were experienced by 61 (42.1%) of participants 
in the FST + CPT group and 68 (47.6%) of participants in the 
MPT +  CPT group. Serious adverse events were experienced 
by 26 (18.0%) of participants in the FST + CPT group and 15 
(10.5%) in the MPT + CPT group. Serious adverse events in the 
MedDRA System Organ Class “nervous system disorders” were 
experienced by six (4.1%) of participants in the FST + CPT group 
and two (1.4%) of people in the MPT + CPT group.
health economics
Intervention Cost
The FST equipment cost was estimated to be £898.74; when 
divided across the 145 participants allocated to the FST interven­
tion this equates to £6.20 per participant (Table 11). A total of 
eight FST training workshops took place, where the length varied 
between 1 and 10 h (the latter was spread over 2 days). Trainer 
time was estimated as a cost of £3,782 (61 h in total, including 8 h 
preparation); trainee time was estimated as £4,488 (102 h in total; 
and travel, accommodation and room hire costs were estimated 
at £7,016). This equated to a total of £15,286, or an estimated 
£105.42 per FST participant (Table 11).
Other NHS and PSS Costs
Details of the available resource use data are provided in Table 11. 
The unit costs that were assigned to the resource use items, to pro­
duce the cost estimates are reported in Table 12. Details of medi­
cation (prescribed by the doctor) were provided by 78 (54.5%) of 
the 143 MPT + CPT participants, and by 78 (53.8%) of the 145 
FST + CPT participants. Participants in both groups reported a 
considerable number of visits from health professional—a mean 
of 58 per participant over the 6­month follow­up period in the 
MPT +  CPT group, compared to 109 per participant for the 
FST + CPT group. Indeed, visits from health professional, and 
hospital admission costs, were found to be the two highest cost 
components, whereas, for example, the total A&E visit cost was 
much lower. However, it should be noted that these values can be 
skewed by a few reported high values (Table 11).
Quality of Life Outcomes
The EQ­5D­3L scores were slightly higher for the FST + CPT 
group at baseline, 6­week and 6­month follow­up (Table  12). 
Over the 6  months both the MPT  +  CPT and FST  +  CPT 
group showed a mean increase of 0.121 and 0.131, respectively 
(Table  12). There was no significant difference between the 
groups.
Cost-Effectiveness
The results of the base­case bivariate regression are shown in 
Table 13, where it can be seen that FST + CPT was estimated to 
be associated with a lower cost and slightly lower QALY score. 
The incremental cost (95% CIs) was −£180.35 (−£48,388.28, 
£4,027.58). The associated net­benefit was £114 at an (λ) of 
FigUre 2 | Association between dose (hours) of therapy and response to 
therapy as measured by change in Action Research Arm Test (ARAT) score 
from baseline to outcome. Pearson correlation coefficients for: FST + CPT 
group (n = 101) r = 0.154, p = 0.123; MPT + CPT group (n = 103) r = ‒0.055, 
p = 0.581; and for all participants (n = 204) r = 0.071, p = 0.311.
TaBle 4 | Amount (dose) of CPT and experimental (MPT or FST) delivered and reasons for sessions lasting less than 90 min for all randomised participants (not just 
those with total ARAT score at outcome).
cPT received experimental received
FsT + cPT (n = 145) MPT + cPT (n = 143) FsT + cPT (n = 145) MPT + cPT (n = 143)
Hours of intervention n = 124 n = 124 n = 145 n = 142
Participants with recordsa (n) (85.5%) (86.7%) (100%) (99.3%)
Mean (SD) 7.4 (6.7) 6.7 (5.8) 14.8 (9.9) 19.2 (11.1)
Median (IQR) 5.7 (2.2, 11.1) 5.0 (2.1, 8.9) 13.3 (6.2, 21.5) 18.2 (10.1, 26.6)
Min–Max 0–37.9 0–23.9 0.1–40.9 0–45
Number of sessions n = 126 n = 124 n = 145 n = 142
Participants with records (n) (86.2%) (86.7%) (100%) (99.3%)
Mean (SD) 12.9 (8.9) 12.1 (8.7) 18.0 (8.6) 19.1 (7.9)
Median (IQR) 12.0 (6.0, 18.3) 10.0 (5.0, 19.0) 19.0 (11.0, 25.0) 21.0 (13.8, 26.0)
Min–Max 0–43 0–33 0–42 0–31
Minutes per session n = 124 n = 124 n = 145 n = 142
Participants with records (n) (85.5%) (86.7%) (100%) (99.3%)
Mean (SD) 30.6 (12.9) 30.5 (13.2) 46.2 (16.9) 57.6 (17.9)
Median (IQR) 30.2 (20.0, 40.0) 30.4 (22.0, 38.0) 45.5 (34.0, 56.3) 56.5 (44.1, 71.5)
Min–Max 0–78 0–83 4.0–88.65 0–90
Reason for less than 90 min session time NA NA n = 144 n = 142
Participants with records (n) (99.3%) (99.3%)
% Sessions lasting 90+ min (median, IQR) NA NA 0.0 (0.0, 9.2) 8.3 (0.0, 33.3)
% Fatigued = less than 90 min (median, IQR) NA NA 28.1 (13.3, 42.3) 35.2 (13.3, 60.0)
% Unwell = less than 90 min (median, IQR) NA NA 0.0 (0.0, 3.4) 0.0 (0.0, 4.0)
% Declined = less than 90 min (median, IQR) NA NA 13.3 (3.3, 27.1) 7.3 (0.0, 23.3)
% Other = less than 90 min (median, IQR) NA NA 38.5 (20.0, 64.2) 32.8 (13.3, 60.3)
CPT, conventional physical therapy; MPT, movement performance therapy; FST, functional strength training; IQR, interquartile range; NA, not applicable; ARAT, Action Research  
Arm Test.
aAll randomised participants and not just those with total ARAT scores at outcome.
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£20,000 per QALY. However, neither the difference in mean cost 
nor the difference in mean effect was statistically significant. 
Similarly the CEAC suggests there is a >40% chance of making 
the wrong decision by choosing FST + CPT at an (λ) of £20,000 
per QALY. This demonstrates there is considerable uncertainty 
associated with this result.
Sensitivity Analyses
The results of the five sensitivity analyses are shown in Table 13. 
In line with the base­case results, there were no significant differ­
ences between the mean costs or mean effects between groups. 
Similarly, the probability of making the wrong decision by choos­
ing a particular option was always >25% according to the CEAC 
[at an (λ) of £20,000 per QALY], again suggesting that there is 
considerable uncertainty.
DiscUssiOn
summary of Main results
Clinical Efficacy
Small differences between the groups in upper limb recovery 
were found for some measures, but, these were neither clinically 
important nor statistically significant. The variability within 
groups was considerable especially for (hand) grip force and 
(finger) pinch force.
Neural Correlates of Clinical Improvement
This study found no clinically important association between 
clinical improvement and change in the neural measures in 
response to either trial intervention. However, the sample sizes 
available for analysis of neural–therapy interactions were small 
for reasons including: lack of consent for these measures; lack 
TaBle 5 | Treatment content for all randomised participants: percentage of 
sessions in which specific treatment categories were provided.
Functional 
strength training 
(FsT) + conventional 
physical therapy (cPT) 
(n = 145)
Movement 
performance 
therapy 
(MPT) + cPT 
(n = 143)
Percentage  
sessions,  
median (iQr)
Percentage 
sessions, 
median (iQr)
cPT
Number participants with 
treatment records
125 (86.2%) 125 (87.4%)
Soft tissue mobilisation 0.0 (0.0, 16.7) 0.0 (0.0, 23.6)
Joint movement and 
mobilisation—isolated
40.0 (8.1, 68.0) 47.6 (7.4, 71.3)
Facilitation muscle activity and 
movement
33.3 (5.9, 71.0) 34.8 (9.2, 68.2)
Positioning 6.3 (0.0, 39.4) 9.5 (0.0, 49.0)
Specific sensory input 0.0 (0.0, 13.4) 0.0 (0.0, 14.3)
Exercise to increase strength 40.9 (11.6, 74.7) 30.0 (0.0, 69.6)
Balance and mobility 
incorporating upper limb
59.3 (20.0, 83.3) 35.7 (0.0, 73.4)
Upper limb functional tasks 60.0 (23.9, 84.5) 40.0 (18.3, 78.9)
Education for patient or carer 10.0 (0.0, 39.4) 10.0 (0.0, 44.2)
FsT
Number participants with 
treatment records
144 (99.3%) 0
Muscle group/s specific 
movement
100.0 (94.4, 100.0) 0
Hand reach/retrieval activity 80.0 (56.3, 94.7) 0
Hand reach/retrieval in side lying 0.0 (0.0, 5.4) 0
Hand grip 83.3 (53.4, 96.3) 0
Hand manipulation activity 73.2 (37.6, 95.5) 0
MPT
Number participants with 
treatment records
0 142 (99.3)
0
Soft tissue mobilisation 0 31.3 (0.0, 83.8)
Joint movement and 
mobilisation—isolated
0 100.0 (85.4, 
100.0)
Facilitation of muscle activity and 
movement
0 75.0 (29.5, 96.4)
Positioning 0 50.9 (15.1, 91.2)
Specific sensory input 0 45.6 (10.7, 80.6)
Exercise to increase strength 0 69.2 (37.5, 91.7)
Balance and mobility 
incorporating upper limb
0 7.4 (0.0, 40.3)
Upper limb functional tasks 0 92.9 (77.3, 100.0)
Education for patient or carer 0 55.6 (17.9, 82.4)
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time point) for people recruited from consecutive admissions to 
stroke services. In common with the neural correlates of clinical 
improvement analysis the sample sizes available for analysis of 
neural–therapy interactions were smaller than anticipated.
Estimate of Cost-Effectiveness
There were no significant differences in mean cost or mean QALY 
score between the groups.
strengths and limitations
Bias protection for this trial was provided by concealment of 
randomisation order and group allocation via an independent 
telephone randomisation service, and reporting all planned out­
comes. Importantly, trial procedures included blinding of asses­
sors to group allocation. However, because of staffing challenges 
in centres at some points in the trial it was not always possible 
to have blinded assessment of the behavioural outcomes (ARAT, 
WMFT, grip force, and pinch force). Moreover, because both 
experimental interventions were behavioural, it was not possible 
to blind research therapists or participants to group allocation. 
Although non­blinding to group allocation is a limitation for 
trials of pharmaceutical agents, blinding is not always possible 
in trials of many stroke rehabilitation interventions [e.g., Ref. 
(61, 91)]. However, to maximise the blinding of clinical staff to 
participants’ group allocation, the research team did not reveal 
which intervention was allocated and which research therapist 
was delivering which experimental intervention.
The sample size for this trial was estimated by a power calcula­
tion informed by data from an early phase trial of FST + CPT 
and MPT (CPT) + CPT (32). The estimated sample size allowed 
for an attrition rate of 10% at the primary time point of outcome. 
In the event, our attrition rate at outcome was 12.5% which is 
substantially lower than the 25% reported by the EXCITE Trial 
(92), similar to the 12.7% reported by the ICARE trial (61) and 
just below the 14% reported by the EVREST trial (91). A strength 
of the power calculation was that it considered the anticipated 
clustering of participants within therapists. However, staff turno­
ver resulted in more therapists providing either MPT or FST for 
participants than was envisaged originally. Although this limited 
the level of clustering of participants within therapists, it is also 
a strength because a larger number of therapists provides greater 
generalisability to clinical practice.
At baseline, 59% of participants were recruited within 30 days of 
stroke and 41% recruited at 31 days or more (Table 2). To minimse 
potential differences in response to therapy the randomisation 
process considered this in the stratification. This was successful at 
balancing time after stroke between the groups (Table 2).
The recruitment rate for this FAST­INdiCATE trial was 5.7% 
of those screened, which is within the range of those reported for 
recent respected trials of physical therapy interventions in the first 
3 months after stroke, e.g., 3.3% (61), 8.3% (93), and 15.8% (91).
This trial was congruent with the requirements for stroke reha­
bilitation trials (21, 62, 94). A key strength for all aspects of this 
trial is that the experimental interventions, both MPT and FST, 
were described in sufficient detail to enable both research replica­
tion of the trial and transferability of results to clinical practice 
(15, 95, 96). Thus, this trial has followed the recommendations 
of equipment availability; contraindications to MRI and/or TMS; 
and a participant being unable to attend a measurement session. 
In addition, the simple neural measures that are the focus of this 
report may not capture the most relevant or sensitive features of 
residual brain structure and function.
Predictive Markers of Clinical Improvement
This study found no interaction effects between baseline neural 
variables and change in ARAT total score (primary outcome 
measure) for the more paretic (contralesional) upper limb over a 
6­week intervention (between baseline and the primary outcome 
TaBle 8 | Change (outcome—baseline) in neural variables for participants with data at both visits for functional strength training (FST) + conventional physical therapy 
(CPT) and movement performance therapy (MPT) + CPT groups.
Variable group N Baseline:  
mean (sD)
Outcome:  
mean (sD)
change:  
mean (sD)
least squares: mean 
(95% ci)
least squares mean  
difference (95% ci), p-value
Lesion volume, mm3 
(log-transformed)
FST + CPT 24 8.20 (2.13) 8.10 (2.17) −0.10 (0.45) −0.11 (−0.31, 0.09) −0.12 (−0.36, 0.13); p = 0.349
MPT + CPT 20 8.20 (2.49) 8.10 (2.40) −0.00 (0.32) 0.01 (−0.21, 0.22)
Corticocortical connectivitya FST + CPT 20 0.38 (0.09) 0.38 (0.09) −0.00 (0.02) −0.01 (−0.02, 0.01) 0.01 (−0.01, 0.03); p = 0.386
MPT + CPT 18 0.45 (0.07) 0.43 (0.08) −0.01 (0.03) −0.02 (−0.03, −0.00)
Corticospinal connectivityb FST + CPT 20 0.03 (0.05) 0.03 (0.04) 0.00 (0.01) 0.00 (−0.01, 0.02) −0.01 (−0.02, 0.01); p = 0.524
MPT + CPT 18 0.01 (0.05) 0.031 (0.05) 0.02 (0.04) 0.01 (−0.01, 0.03)
RMT pBB FST + CPT 28 61.6 (12.07) 60.6 (13.61) −1.0 (14.27) −0.82 (−6.32, 4.68) −2.87 (−8.91, 3.16); p = 0.343
MPT + CPT 27 62.5 (13.83) 65.0 (14.90) 2.5 (10.06) 2.06 (−3.86, 7.97)
RMT pECR FST + CPT 28 53.1 (13.15) 52.0 (11.62) −1.1 (11.46) −3.29 (−7.68, 1.09) 0.98 (−4.31, 6.28); p = 0.710
MPT + CPT 27 57.4 (17.16) 53.2 (12.93) −4.2 (12.98) −4.28 (−9.19, 0.63)
RMT pBB, resting motor threshold paretic Biceps brachii; RMT pECR, resting motor threshold paretic extensor carpi radialis; 95% CI, 95% confidence interval.
aFractional anisotropy MNI corpus callosum.
bAsymmetry ipsilesional:contralesional Montreal Neurological Institute corticospinal tract.
TaBle 7 | Change from baseline to outcome and follow-up for secondary outcomes, Wolf Motor Function Test performance (WMFT), grip force, and pinch force, 
paretic (contralesional) upper limb for participants with data at both time points.
comparison Treat group number 
participantsa
Baseline: 
mean (sD)
Outcome: 
mean (sD)
change: 
mean (sD)
least squares: mean 
[95% confidence 
interval (95% ci)]
least squares mean 
difference (95% ci) and 
p-value of change between 
group
WMFT
At outcome Functional 
strength training 
(FST) + conventional 
physical therapy (CPT)
117 36.60 (19.97) 47.80 (19.70) 11.20 (10.62) 11.31 (0.35, 13.27) 0.65 (−1.91, 3.21); p = 0.616
Movement performance 
therapy (MPT) + CPT
109 39.00 (16.84) 49.00 (18.52) 10.00 (9.61) 10.65 (8.62, 12.69)
At follow-up FST + CPT 98 38.30 (19.42) 51.80 (19.83) 13.50 (14.28) 14.21 (11.53, 16.88) 0.01 (−3.46, 3.47); p = 0.997
MPT + CPT 93 39.30 (16.96) 52.60 (18.41) 13.30 (11.55) 14.20 (11.40, 17.00)
grip force
At outcome FST + CPT 122 7.60 (8.72) 10.7 (9.99) 3.1 (7.11) 3.98 (2.74, 5.21) 0.47 (−1.16, 2.09); p = 0.571
MPT + CPT 115 7.20 (8.19) 9.90 (9.35) 2.70 (6.25) 3.51 (2.24, 4.78)
At follow-up FST + CPT 101 7.40 (8.50) 11.80 (10.20) 4.4 (7.02) 5.33 (3,70, 6.95) −0.29 (−2.37, 1.79); p = 0.785
MPT + CPT 97 7.20 (8.35) 12.00 (10.10) 4.70 (8.71) 5.62 (3.95, 7.28)
Pinch force
At outcome FST + CPT 115 2.20 (2.20) 3.00 (2.93) 0.90 (2.13) 0.91 (0.48, 1.33) 0.02 (−0.54, 0.59); p = 0.934
MPT + CPT 109 2.00 (2.30) 2.90 (2.88) 0.90 (2.16) 0.89 (0.45, 1.32)
At follow-up FST + CPT 94 2.30 (2.22) 3.30 (2.45) 1.00 (2.19) 1.16 (0.62, 1.71) −0.30 (−0.98, 0.39); p = 0.395
MPT + CPT 95 2.10 (2.24) 3.50 (3.09) 1.40 (2.76) 1.46 (0.92, 2.01)
aNumber of participants with data at both time points.
TaBle 6 | Change from baseline to outcome and follow-up for primary outcome, Action Research Arm Test score, paretic (contralesional) upper limb for participants 
with data at both time points.
comparison Treat group number 
participantsa
Baseline: 
mean (sD)
Outcome: 
mean (sD)
change: 
mean (sD)
least squares: mean 
[95% confidence 
interval (95% ci)]
least squares mean 
difference (95% ci) and p-
value of change between 
group
At outcome Functional strength training 
(FST) + conventional  
physical therapy (CPT)
126 24.40 (18.45) 34.10 (17.81) 9.70 (11.72) 9.80 (7.87, 11.73) 1.35 (−1.20, 3.90); p = 0.298
Movement performance 
therapy (MPT) + CPT
114 26.50 (17.78) 34.40 (18.68) 7.90 (9.18) 8.45 (6.41, 10.49)
At follow-up FST + CPT 104 25.80 (18.21) 36.80 (19.14) 11.10 (14.68) 10.90 (8.31, 13.49) 0.55 (−2.77, 3.88); p = 0.743
MPT + CPT 100 27.10 (17.49) 37.40 (17.50) 10.3 (10.74) 10.35 (7.66, 13.03)
aNumber of participants with data at both time points.
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TaBle 9 | Correlations between change (from baseline to outcome) in neural correlates and paretic ARAT total score (primary outcome measure).
FsT + cPT MPT + cPT all
number r-Value p-Value number r-Value p-Value number r-Value p-Value
Volume of stroke lesion 24 −0.021 0.921 19 −0.043 0.863 43 −0.042 0.787
Corticocortical anatomical connectivity 20 0.092 0.699 17 −0.029 0.913 37 0.069 0.684
Corticospinal anatomical connectivity 20 −0.031 0.897 17 −0.306 0.232 37 −0.147 0.385
RMT—pBB 28 0.095 0.631 27 0.199 0.320 55 0.093 0.501
RMT—pECR 28 −0.080 0.635 27 0.043 0.831 55 −0.001 0.996
CST, corticospinal tract; pBB, paretic biceps brachii; pECR, paretic extensor carpi radialis muscle; FST, functional strength training; CPT, conventional physical therapy; MPT, 
movement performance therapy; ARAT, Action Research Arm Test; RMT, resting motor threshold.
TaBle 10 | Subgroup analysis of interaction effect between baseline neural variables and change in paretic Action Research Arm Test (ARAT) total score from baseline 
to outcome.
FsT + cPT paretic araT MPT + cPT paretic araT least squares  
mean difference 
(95% ci)
interaction 
p-value
N Baseline:  
mean (sD)
change at 
outcome:  
mean (sD)
N Baseline:  
mean (D)
change  
at outcome: 
mean (sD)
MNI CST affecteda No 5 27.0 (17.07) 17.2 (13.65) 7 27.6 (23.59) 6.1 (7.13) 20.64 (−14.07, 55.36) 0.384
Yes 33 23.3 (19.67) 11.9 (12.32) 27 25.7 (17.04) 8.3 (7.40) 2.88 (−2.29, 8.04)
Volume of stroke lesion (logged) <Median 17 25.1 (18.64) 16.1 (11.99) 20 28.7 (18.96) 9.7 (8.03) 5.30 (−1.09, 11.70) 0.762
≥Median 21 22.8 (19.99) 9.8 (12.36) 14 22.4 (16.98) 5.4 (5.39) 4.44 (−2.89, 11.76)
FA MNI corpus callosum midlineb <Median 18 27.4 (20.29) 8.2 (9.47) 14 27.4 (17.53) 6.6 (6.87) 3.83 (−2.41, 10.07) 0.723
≥Median 18 22.3 (18.22) 17.1 (13.45) 18 24.6 (17.74) 9.2 (6.78) 4.29 (−2.99, 11.58)
Asymmetry MNI CSTc,d <Median 19 28.6 (16.69) 14.6 (11.90) 16 31.9 (15.80) 10.4 (6.65) 2.42 (−3.95, 8.79) 0.553
≥Median 17 20.6 (21.36) 10.4 (12.73) 16 19.7 (17.26) 5.7 (6.35) 6.62 (−0.33, 13.56)
Presence of MEP pBBe No 16 12.6 (15.34) 9.4 (11.43) 13 12.7 (13.31) 9.5 (7.41) −0.60 (−7.38, 6.18) 0.237
Yes 34 32.2 (16.69) 10.9 (11.85) 36 34.0 (15.05) 6.2 (7.95) 3.19 (−0.71, 7.09)
pBB resting motor threshold <Median 15 37.8 (12.86) 9.3 (8.83) 16 36.6 (15.29) 5.7 (7.37) 3.17 (−2.27, 8.62) 0.697
≥Median 19 27.7 (18.29) 12.1 (13.90) 20 32.0 (14.92) 6.7 (8.54) 2.89 (−3.11, 8.88)
Presence of MEP pECRf No 14 10.4 (13.15) 7.1 (8.98) 11 9.7 (12.62) 8.1 (9.31) −1.74 (−9.54, 6.07) 0.193
Yes 36 31.9 (16.87) 11.7 (12.37) 38 33.8 (14.60) 6.8 (7.52) 3.41 (−0.53, 7.34)
pECR resting motor threshold <Median 18 35.6 (16.02) 12.1 (11.41) 15 40.2 (8.39) 5.9 (6.19) 2.30 (−1.74, 6.34) 0.503
≥Median 18 28.3 (17.35) 11.3 (13.58) 22 29.5 (16.71) 7.6 (8.47) 2.57 (−4.06, 9.21)
aCorticocortical anatomical connectivity.
bFA = Fractional anisotropy.
cCorticocortical anatomical connectivity (ipsilesional:contralesional).
dCST = Corticospinal tract.
eMEP pBB = Motor evoked potential paretic biceps brachii.
fpECR = Paretic extensor carpi radialis.
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for improving rehabilitation research (15, 94, 97). A particular 
strength of this trial is the complete reporting of the content 
and dose of therapy that was actually provided, including the 
CPT, since the majority of stroke rehabilitation studies do not 
report fidelity to intended therapy (91, 97). When information 
is reported it is usually in terms of dose rather than content (61).
Another important strength of this trial is that 59% of par­
ticipants provided informed consent within 30  days of stroke. 
Early rehabilitation is recommended because the brain has most 
potential for reorganisation, particularly in the first month after 
stroke, but also in the following 2 months (9). In clinical practice, 
most rehabilitation is provided in this early period, and yet most 
rehabilitation trials are conducted later in recovery (21, 98). 
Moreover, participants in this trial were representative of those 
who receive upper limb rehabilitation in clinical stroke services 
and not just those with moderate or mild paresis. The results are 
therefore directly relevant to clinical practice.
A key strength of this trial is that mechanistic studies were 
integral to the design. In addition, the present trial has addressed 
the need to investigate both the underlying mechanisms of effect 
of stroke rehabilitation interventions and which people are most 
likely to respond to which interventions (16, 17, 21, 99). Thus, 
unlike many mechanistic studies, those underpinning this study 
guarded against potential risk of bias and allowed for sufficient 
description of the interventions provided.
However, disappointingly, analysis of the neural correlates 
study was restricted by the unanticipated low proportion of par­
ticipants who had both (a) full sets of clinical data and (b) neural 
measures at the key time points of baseline and outcome. This 
ranged from 37 participants for corticocortical anatomical con­
nectivity to 55 participants for RMT in pBB and pECR muscles. 
Likewise, the predictive markers analysis was also restricted by 
the smaller than expected number of participants. Nevertheless, 
although the number of participants was lower than anticipated 
TaBle 12 | Quality of life outcomes (available case, per participant).
item mean score (sD) (n) FsT + cPT 
(N = 145)
MPT + cPT 
(N = 143)
p-Value
Baseline EQ-5D-3L score 0.428 (0.332) 
(n = 140)
0.421 (0.326) 
(n = 143)
0.860
6-week EQ-5D-3L score 0.523 (0.308) 
(n = 124)
0.508 (0.324) 
(n = 117)
0.728
6-month EQ-5D-3L score 0.566 (0.297) 
(n = 103)
0.562 (0.313) 
(n = 99)
0.939
EQ-5D-3L 6-month change score 0.131 (0.305) 
(n = 101)
0.121 (0.301) 
(n = 99)
0.815
QALY score (over 6 months) 0.266 (0.134) 
(n = 101)
0.266 (0.137) 
(n = 99)
0.995
n, Number for whom data were available; QALY, Quality-Adjusted Life Years; FST, 
functional strength training; CPT, conventional physical therapy; MPT, movement 
performance therapy.
TaBle 11 | Levels of resource use (available case, per participant over the 6-month follow-up period) and mean participant costs (£) (complete case participants 
unadjusted).
resource use Participant costs
FsT + cPT (N = 145) MPT + cPT (N = 143) FsT + cPT (N = 56) MPT + cPT (N = 143) p-Value
Visits from health professionals visit (mean) 108.84 (500.78) (n = 102) 57.81 (63.56) (n = 100) 2,725.81 (2,315.29) 2,719.03 (2,381.39) 0.900
Occupational therapist 9.87 (17.25) (n = 102) 8.52 (11.58) (n = 100) 553.84 (795.33) 548.76 (703.74) 0.971
Social worker 0.73 (1.37) (n = 102) 0.86 (1.50) (n = 100) 54.89 (107.72) 103.73 (186.70) 0.083
Speech and language therapist 2.45 (6.78) (n = 102) 1.97 (5.75) (n = 100) 186.68 (525.73) 180.36 (522.09) 0.948
Nurse 3.25 (6.63) (n = 102) 5.01 (12.54) (n = 100) 82.56 (186.25) 115.71 (251.76) 0.423
GP 2.73 (4.95) (n = 102) 2.10 (1.85) (n = 100) 106.77 (86.24) 104.26 (90.85) 0.879
Community care assistant 69.17a (502.73) (n = 102) 17.50 (54.71) (n = 100) 448.67 (1,404.37) 191.98 (471.15) 0.197
Physiotherapist 18.19 (21.08) (n = 102) 19.78 (19.92) (n = 100) 1,265.27 (1,201.70) 1,314.77 (1,409.25) 0.839
Other 2.47 (13.68) (n = 102) 2.07 (12.48) (n = 100) 75.13 (444.44) 159.45 (1,123.31) 0.600
Hospital admissions (mean bed days) 9.15 (21.82) (n = 92) 10.49 (25.36) (n = 91) 2,625.74 (6,018.34) 4,259.14 (8,606.40) 0.234
Accident and emergency (mean visits) 0.25 (0.70) (n = 102) 0.32 (0.66) (n = 103) 13.76 (34.02) 26.85 (61.27) 0.161
Alternative residences (mean weeks) 0.57 (2.36) (n = 102) 0.45 (2.62) (n = 103) 4.35 (32.55) 364.32 (2,447.58) 0.274
Nursing home 0.00 (0.00) (n = 102) 0.06 (0.59) (n = 103)
Residential care 0.51 (2.30) (n = 102) 0.35 (2.53) (n = 103)b
Other 0.06 (0.59) (n = 102) 0.05 (0.41) (n = 103)
NHS/PSS professional carer (mean hours) 2.68 (3.90) (n = 86) 1.74 (4.82) (n = 91) 2,602.14 (12,774.31) 1,022.75 (2,964.16) 
(134.30)
0.350
Prescriptions (mean number) 4.82 (3.01) (n = 78) 4.81 (3.00) (n = 78) 315.61 (1,162.04) 175.03 (242.30) 0.358
FST training 105.42 (0.00) 0 <0.001
FST equipment 6.20 (0.00) 0 <0.001
Overall NHS and PSS costs 8,447.03 (13,816.73) 8,567.13 (9,623.58) 0.977
N, Number of patients in receipt; n, number of patient for whom data were available; PSS, Personal Social Services; FST, functional strength training; CPT, conventional physical 
therapy; MPT, movement performance therapy.
aThis includes 5,040 visits that were reported by 1 participant. If these data were excluded the mean value would be 19.95.
bOne participant reported that they spent 5 months in residential care.
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initially, there were still substantially more than in many other 
studies. Other studies have also reported challenges in undertak­
ing TMS measurements in stroke survivors, with TMS measures 
reported to have been collected in 33% of a sample of participants 
recruited from a database 4–20 months after stroke (100), which 
is identical to that in this trial (Table 1). Unlike the well­regarded 
PREP algorithm development study (27), participants with 
contraindications to MRI and TMS were not excluded from 
this study. Consequently the smaller than expected number of 
participants with neural measures is likely to be a consequence of 
embedding mechanistic studies into a pragmatic clinical trial. In 
addition, the multicentre design of this study means that different 
scanners were used at different sites and some variation in scan­
ner protocols was unavoidable. This has the potential to introduce 
between­site variability into the imaging­derived metrics that is 
not taken into account in our analysis. Yet, this trial demonstrates 
that mechanistic neural studies can be embedded in pragmatic 
clinical trials. Furthermore, this trial shows that highly special­
ised neurophysical and imaging­based measures can be made 
outside of specialist neurological research centres. The sites for 
this trial had not conducted these mechanistic investigations 
before. However, neural data collection was not problem free, as 
evidenced by the number of measures not undertaken for reasons 
such as (Table 1): not giving informed consent for MRI (19.4% 
at baseline and 26.4% at outcome); not giving informed consent 
for TMS (12.8% at baseline and 15.6% at outcome); unavailability 
of the MR scanner (5.9% at baseline and 6.0% at outcome); and 
unavailability of TMS (8.3% at baseline and 5.8% at outcome).
The inclusion of one of the few health economic investigations 
of well­defined stroke rehabilitation interventions further adds 
strength to this trial. We have identified large cost drivers (i.e., 
visits from health professionals and hospital admissions) and also 
resources that have a relatively low cost, e.g. A&E, visits. There 
is therefore an argument for not including such resource items 
in future studies since they are unlikely to differ between groups 
and, in turn, this would hopefully improve data completeness.
relationship to Previous studies
Therapy Received by Participants
It is reassuring that the dose and content of CPT were essentially 
the same for the two experimental groups but these data indicated 
TaBle 13 | Base-case and sensitivity analyses: incremental cost, incremental effect, and cost-effectiveness of FST + CPT versus MPT + CPT.
analysis (nm, nf) incremental cost  
(95% ci) (£)
incremental effect  
(95% ci)
icer/net 
benefita (£)
ceac± (%)
QalY gain
Base-case: complete case (61, 56) −236.89 (−4,444.81 to 3,971.03) −0.0018 (−0.037 to 0.0330) 200.59a 58.9
SA1: imputed (143, 145) 1,205.60 (−2,196.60 to 4,613.80) 0.0055 (−0.0232 to 0.034) 219,157.06 27.2
SA2: excluding intervention training/equipment costs (61, 56) −348.51 (−4,556.43 to 3,859.42) −0.002 (−0.037 to 0.033) 312.21a 60.1
SA3: including carer costs (paid for privately) (61, 56) −784.75 (−5,712.80 to 4,143.29) −0.002 (−0.037 to 0.033) 747.94a 63.9
SA4: including carer costs (paid for privately) plus any other  
help/care (61, 56)
3,757.301 (−7,598.65 to 15,113.20) −0.002 (−0.037 to 0.033) −3,795.91a 30.7
SA4b: including carer costs (paid for privately) plus any other  
help/care, with inconceivable outliers excludedb (60, 55)
−392.10 (−6,081.78 to 5,297.58) −0.004 (−0.039 to 0.031) 310.43a 54.5
SA5: winsoring (53, 54) −506.80 (−3,038.42 to 2,024.81) −0.001 (−0.038 to 0.036) 488.01a 64.0
95% CI, 95% confidence interval; ICER, incremental cost-effectiveness ratio; Dominant, lower mean costs and higher mean effect; QALY, Quality-Adjusted Life Years; FST, functional 
strength training; CPT, conventional physical therapy; MPT, movement performance therapy.
Nm and Nf equal the number included in the analysis from the MPT + CPT and FST + CPT groups.
SA1, …, SA5 refer to the different sensitivity analyses described in Section Materials and Methods; QALY over 6 months; ±probability of bring cost-effective on the cost-
effectiveness acceptability curve (CEAC) at the threshold (λ) of £20,000 per QALY.
aDenotes only net benefit was reported, ICER not reported as either a negative cost or effect was estimated.
bTwo participants stated a length of care time which exceeded the timeframe in question, i.e., they reported more hours than there are in a week and were dropped from SA4b.
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considerable variance around the mean values for most categories 
of therapy, irrespective of type (Table 5). It is possible that this 
variance is due to differences between participants, and that this 
influenced clinical therapists’ choice of therapy category. It is also 
possible that variance is due to differences between therapists. 
Further investigation of these data will be undertaken and 
reported in a future publication.
Examination of the content of the two experimental interven­
tions could lead to the interpretation that there was overlap, since 
69% of the sessions for the MPT + CPT group included “exercise 
to increase strength,” and 93% included upper limb functional 
tasks. However, the distinction between the content of FST and 
MPT was maintained by adherence to protocol, namely, that: 
(a) any functional tasks and resistance training provided within 
MPT was neither repetitive nor progressed systematically and 
(b) the focus was on intrinsic feedback on movement perfor­
mance through verbal and hands­on techniques. Monitoring 
of adherence to protocol throughout the trial was through 
training sessions and inter­team consultations. In this way, 
any uncertainties about what constituted both MPT and FST 
were addressed with direct reference to the therapy protocols. 
Although it would have been useful to collect more detailed 
information about the precise techniques provided and time 
spent on each within the therapy categories, this was not pos­
sible for pragmatic reasons. However, the description of physical 
therapy interventions provided in this present report is much 
more detailed and replicable than the “black box” descriptions 
of only a few years ago (101, 102).
The protocol stated that participants would be provided with 
up to 90 min of their allocated experimental therapy, up to 5 days 
a week for up to 6 weeks. This was a potential dose of 45 h in 30 
sessions. In the event, mean (SD) hours of therapy were 14.8 (9.9) 
and 19.2 (11.1) for all participants randomised to the FST + CPT 
and MPT + CPT groups, respectively. Most participants were not 
able to tolerate 90 min in one session, fatigue being the most fre­
quent specific single reason (Table 4). The therapy dose reported 
here is lower than the dose of therapy delivered in a preliminary 
dose­ranging trial of arm training (103). However, the dose rang­
ing trial recruited 32 people who were: “able to tolerate the inter­
ventions and evaluations”; following their first­ever stroke; and 
were aged a mean (SD) of 50 (12) years. Whereas the data reported 
here were for all randomised participants, aged approximately 
20 years older than in the dose­ranging trial, from a consecutive 
series of admissions to stroke services, and not just those who 
were judged to be able to tolerate a high dose of therapy. So, the 
present trial is more likely to be representative of current routine 
clinical practice. Furthermore, data in this report relate not just 
to those participants who remained in the trial at outcome and/
or follow­up (Table 4). Planned subsequent analyses will explore 
whether higher doses were delivered to those still in the trial at 
the outcome time point. Although most participants were not 
able to tolerate 90 min in one session they were able to participate 
in sessions lasting a mean (SD) of 46.2 (16.9) and 57.6 (17.9) min 
for the FST + CPT and MPT + CPT groups, respectively. This is 
similar to the 60­min sessions delivered to approximately 77% 
of participants in the ICARE trial (61). When the dose of CPT 
is added to experimental therapy then participants in this trial 
received a similar dose of physical therapy to that received by 
ICARE trial participants (61).
Clinical Efficacy
The results of this trial differ from the early phase findings 
that suggested a trend towards better upper limb recovery, as 
assessed by ARAT score, in response to FST + CPT compared 
to MPT + CPT early after stroke (32). However, the findings of 
the present trial, with a larger sample size, showed no significant 
difference between FST + CPT and MPT + CPT in respect of 
improvement of ARAT score over the 6­week intervention phase. 
It is possible that a difference could have been detected if motor 
impairment had also been measured; however, in the interests of 
minimising burden to participants, we did not undertake these 
measures.
Dose of physical therapy could have been a confounding factor 
for the present results as it has been associated with enhanced 
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outcome [e.g., Ref. (21, 58)]. However, there are systematic review 
findings suggesting that that different forms of physical therapy 
provided to participants in the higher and lower dose groups may 
confound any association (67). Consequently, the association 
(Pearson’s correlation coefficient) between the total dose of CPT 
plus either FST or MPT was scrutinised to check for influence 
on response to therapy dose received. Since no dose effect on 
response to either form of therapy was discernible (Figure  2), 
it appears unlikely that dose of therapy confounded the finding 
of no statistically significant difference between FST + CPT and 
MPT + CPT. Furthermore, there was no between­group differ­
ence in either the dose or the content of CPT.
That MPT +  CPT was found to produce equivalent benefit 
to FST + CPT is interesting, since FST is based on findings that 
task­specific training drives recovery after stroke (104), and that 
the largest impact on upper limb improvement is loss of muscle 
strength (19, 20). By contrast, MPT concentrates on enhancing 
the quality of movement during whole or part functional tasks 
and not on repetitive progressive training of those everyday 
tasks. Equivalence of effect is not expected from interpretations 
of evidence indicating that therapy should be repetitive and 
task­orientated/specific (105, 106). However, a recent systematic 
review concludes that the evidence for repetitive task training is 
of low quality (7), the ICARE trial of task­orientated upper limb 
rehabilitation found that recovery was equivalent to an equal 
dose of therapy­as­usual for people recruited a mean of 46 days 
after stroke (61), and an overview of systematic reviews included 
interventions for sensory impairment in the list of interventions 
for which there was moderate­quality evidence of benefit (107). 
In addition, there is some evidence of effect of such impairment­
based therapy (43) and a meta­analysis found that conceptually 
different physical therapies have equal efficacy (4). It appears 
therefore that MPT is equally as beneficial as FST when given in 
addition to CPT.
Noticeable from these results is that there is substantial varia­
tion around the mean change from baseline for both FST + CPT 
and MPT + CPT (Table 6). So, the present findings support the 
concept underlying the scientific driver for this trial, namely: 
that the population of stroke survivors exhibit interindividual 
differences in recovery (8, 27) and may respond differently to 
different physical therapies (15, 20). This was not unexpected 
as it has been reported for other trials of physical therapies 
[e.g., Ref. (91)] and recognised as an important area for rehabili­
tation research (21, 25).
Predictive Markers of Response
The trial reported here is most likely one of the first trials of peo­
ple recruited from consecutive admissions to a stroke service and 
designed to identify predictive markers of response to specific 
physical therapies early after stroke. Indeed, only six randomised 
controlled trials were included in a recent systematic review of 
predictive markers, none of which investigated stroke rehabilita­
tion (108).
It was anticipated that data from the embedded investigation 
of predictive markers of response would provide some explana­
tion of the variation of response to the experimental therapies 
(25, 109). Indeed, previous studies have indicated that combining 
neuroimaging and neurophysiological measures such as cor­
ticospinal tract integrity (DTI), corpus callosum connectivity 
(DTI), presence of a motor­evoked potential in response to TMS, 
corticocortical connectivity, and corticospinal connectivity may 
be predictive markers of recovery (25, 110). These observations 
have been used in the PREP algorithm to enable prediction of 
recovery at 12 weeks after stroke (27). Comparison of the present 
trial with the PREP algorithm indicates several reasons why find­
ings might differ.
First, the time points for outcome were different. The PREP 
algorithm begins assessment at 72  h after stroke with clinical 
measures of ability to contract contralesional muscle. Then at 
2 weeks after stroke, those stroke survivors not scoring at least 
80% on the clinical measure undertake TMS measures for 
presence of an MEP in ECR and if this is absent then MRI is 
undertaken for DTI measurement of the structural integrity 
of the corticospinal pathway. In the trial reported here, most 
measures were undertaken later, with 41% providing informed 
consent at 31 or more days after stroke. It is possible therefore 
that measurement undertaken more than 2 weeks after stroke has 
less predictive power.
Second, the interventions could have been different. Although 
it is clear that the experimental interventions in both investiga­
tions were delivered in addition to routine therapy information 
about the content and dose of experimental therapy delivered to 
participants in the PREP study is not provided.
Third, there is a difference between definitions of outcome. 
The present trial was concerned with predicting response to 
therapy, change in ARAT score over a 6­week intervention phase; 
whereas the PREP algorithm has been developed to predict actual 
ARAT score at 12 weeks after stroke. Further investigation of data 
from the present trial will not be able to investigate this possibility 
because of the different measurement time points to those used in 
the PREP algorithm development study.
There have been some other investigations of predictive mark­
ers but their findings are of limited benefit for use with people 
early after stroke because of: lack of a comparator group; lack of 
specification of the therapy; participants with higher ability for 
voluntary movement than those in this trial, participants younger 
than those in this trial, and/or participants in the chronic phase 
after stroke (26, 109, 111, 112). Secondary analysis of the move­
ment, MR and TMS measures undertaken in the present trial may 
therefore provide insight into predictive markers of response. 
This secondary investigation will be reported in subsequent 
publications.
Neural Correlates of Improvement
Although there have been reports of differences in neural changes 
in response to physical therapies which vary in efficacy (113–116), 
the current trial found no difference in the neural correlates of 
response between the experimental therapies of FST and MPT 
(Tables 8 and 9). This could be because no statistically significant 
differences were found between the two groups for any of the 
clinical efficacy measures (Tables 6 and 7).
Another explanation for the finding of no difference in the 
neural correlates of response to FST and MPT in the present trial 
is that previous studies were undertaken with smaller sample 
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sizes, e.g., n = 13 (113), n = 12 (114), n = 14 (115), and n = 23 
(116), thus increasing the chances of false positive findings. These 
compare with the sample sizes in the present trial for the MRI 
variables, n = 38, and the TMS variables, n = 55. In addition, the 
earlier studies have potential risk of bias respecting: randomisa­
tion process (113–115); observer­blind assessments (113, 114); 
selective recruitment (114, 115); and from results emanating 
from a post hoc analysis of an RCT (116). However, there may 
be genuine associations which are too subtle to identify with the 
available sample sizes in this trial.
It is possible that the neurophysiological mechanisms underly­
ing therapy­induced improvements are more discrete than can 
be identified by the simple TMS or MR­based measures reported 
here. For example, an early phase investigation of potential 
underlying mechanisms of therapy­induced improvements found 
variation between individuals, which could be influenced by the 
level of residual voluntary motor activity capacity (117). People 
with lower motor activity capacity during the early period of 
therapy were more likely to have fewer muscle synergies and more 
co­contraction than people with higher motor activity capacity 
(117). By the end of the therapy period, those participants with 
lower motor activity capacity initially had increased the number 
of muscle synergies underlying functional movement (117). The 
present trial did not measure muscle synergies.
An alternative reason for lack of correlation between change 
in the neurophysiology measures and change in upper limb 
activity capacity could be because of interindividual differences 
in response to various forms on non­invasive brain stimulation, 
including TMS, in both people after stroke and neurologically 
intact adults (118–120). Furthermore, comparison with other 
studies is limited as amongst TMS studies there has been vari­
ation in the protocols used to derive the neural correlates with 
differences in the method of collecting MEPs (recruitment curve 
or Block of MEPs) and characteristics of recruitment curve 
(intensities of stimulation, number of stimuli, increments of 
intensity, and number of intensities). All these protocol differ­
ences may lead to lack of comparability across studies.
Turning to the MR data, very simple measures, which are 
realistic to quantity in a clinical setting, have been the focus of the 
current report. However, the MR data acquired here could also be 
interrogated with more sophisticated analysis approaches. Future 
reports will determine whether such approaches offer increased 
sensitivity to clinically relevant neural change or prediction of 
response to therapy.
Estimated Cost-Effectiveness
We are only aware of one previous study that has investigated the 
cost­effectiveness of FST poststroke (121). Chan (121) developed a 
decision analytical model to estimate the costs and benefits associ­
ated with CPT + FST over a 2­year period, where the comparators 
were both another increased therapy intervention (CPT + CPT) 
and CPT alone. Overall, in the earlier study CPT + FST was esti­
mated to be more cost­effective than CPT + CPT, largely because 
the improvement in EQ­5D scores was estimated to be higher 
for those in receipt of FST (41). Chan (121) based the EQ­5D 
scores on the work by Cooke and colleagues (41), and our present 
results are in line with these in that we found both groups had an 
improvement in EQ­5D scores. However, the earlier investiga­
tion (41) found that the size of improvement (based on median 
scores and a smaller sample than in our study) was greater for 
CPT + FST compared to CPT + CPT, although in keeping with 
our results there was no significant difference between groups. 
It is difficult to compare our cost estimates to those of Chan 
(121), as (for the reasons outlined earlier) we have not explicitly 
estimated therapy costs. However, in keeping with our results, 
Chan (121) concluded that there was a large level of uncertainty 
associated with results.
generalisability
The generalisability of this trial is considered in the wide inclu­
sion criteria with direct relevance to clinical practice and the 
conduction of the trial in three different clinical centres.
An economic evaluation, where the costs and benefits of 
CPT + MPT were compared to those for CPT + FST, was under­
taken. In addition, the estimation of cost­effectiveness is an 
iterative process, and early information on costs and effects can 
be used to inform the design of subsequent phase III studies.
cOnclUsiOn
The trial reported here combined investigation of the underlying 
mechanisms of motor recovery and predictive markers of ben­
eficial response in a representative sample of people early after 
stroke with substantial to moderate upper limb motor impair­
ment receiving well­characterised physical therapies. There were 
small differences in the clinical efficacy of upper limb recovery 
between FST and MPT given in addition to CPT but these did 
not reach statistical significance. Both groups showed increases 
in ARAT score (primary outcome measure) above the clinically 
important change. However, variation around the mean change 
from baseline scores was substantial in both groups.
The finding of no difference between two such conceptu­
ally different physical therapies is not congruent with clinical 
guidelines (106) and neuroscience principles (9) both of which 
point to advantages of task­specific training such as FST. The 
findings presented here, together with the results of the ICARE 
Trial (61), question the current emphasis on high­dose task­
specific training early after stroke, particularly since there were 
no significant differences in mean cost or mean QALY score 
between the two groups.
The substantial variation around the mean improvement 
from baseline scores was expected from the previous early 
phase trials (32, 41), hence designing the trial reported here to 
embed explanatory neural investigation of FST and MPT for 
(a) predictive markers of response and (b) neural correlates of 
response. The findings were that none of the pretreatment neural 
characteristics of interest predicted response to either FST or 
MPT; and that the neural correlates of change were similar for 
the two forms of physical therapy. Consequently, there is still an 
urgent need for evidence to guide clinical decisions about: (a) 
appropriate prescription of physical therapy for individuals and 
(b) the recovery mechanisms at which physical therapy should be 
targeted (15, 16, 99).
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